23 results
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
23 May 24
Other Events
5:41pm
sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
15 May 24
Results of Operations and Financial Condition
4:34pm
Results R&D expense for the first quarter of 2024 was $7.6 million, compared to $5.5 million for the first quarter of 2023. The increase in R&D expense … is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. The Company’s R&D pipeline
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
5 Apr 24
Other Events
4:33pm
. The Company’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008
8-K
EX-99.1
ELTX
Elicio Therapeutics Inc.
29 Mar 24
Results of Operations and Financial Condition
8:35am
treatment related adverse events were observed. 2023 Financial Results R&D expense for 2023 was $23.8 million, compared to $18.1 million for 2022 … . The increase in R&D expense was primarily due to increased manufacturing and clinical trial expenses as Elicio initiated the AMPLIFY-7P Phase 1a study
8-K
EX-99.2
87j1smcys605s ye4d
9 Jan 24
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
8:11am
8-K
EX-99.1
gw6edeexyqx09p81ga
9 Nov 23
Results of Operations and Financial Condition
4:41pm
8-K
EX-99.2
wdpl4lx jxk87ekn3gq3
27 Sep 23
Other Events
5:41pm
8-K
EX-99.1
kf4am7wk d41rsmisrk
11 Aug 23
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides
11:42am
8-K
ew8q6
2 Jun 23
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
4:36pm
S-4/A
EX-10.30
vxiqwzsg 0owjfd946
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
S-4/A
EX-10.32
te5jw3u h16nx
29 Mar 23
Registration of securities issued in business combination transactions (amended)
5:29pm
8-K
EX-99.1
u61p q8d9kpomzzo
30 Mar 22
Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
4:52pm
8-K
EX-99.1
aokb55947mz g5vvnls
12 Nov 21
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
7:05am
8-K
EX-99.1
5ypga3
12 Aug 21
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
4:10pm